search
Back to results

A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART)

Primary Purpose

Colorectal Cancer, Bowel Cancer

Status
Recruiting
Phase
Phase 2
Locations
United Kingdom
Study Type
Interventional
Intervention
Artesunate 200mg
Placebo
Sponsored by
St George's, University of London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Cancer focused on measuring Artesunate, Artemisinins, Antimalarial, Neoadjuvant, Pre-operative

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  1. Aged 18 or over
  2. Histologically proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer
  3. Stage II/III colorectal cancer planned for surgical resection and no clinical indication for neoadjuvant preoperative chemotherapy/chemoradiation therapy
  4. WHO performance status 0,1 or 2
  5. Adequate full blood count: White Cell Count (WCC) >3.0 x 10^9 /l; Platelets >100 x 10^9/l; Haemoglobin (Hb) >80g/L
  6. Adequate renal function: Glomerular Filtration Rate >30ml/min by Cockcroft-Gault formula
  7. Adequate hepatobiliary function : Bilirubin < 3 x Upper limit normal
  8. Female participants of child bearing potential must have a negative pregnancy test < 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention
  9. Male participants with a partner of childbearing potential must agree to use adequate, medically approved contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention
  10. Patient able and willing to provide written, informed consent for the study.

Exclusion criteria

  1. Contraindication to the use of artesunate due to hypersensitivity
  2. Pregnancy or lactation
  3. Male or female participants unwilling to use an effective method of birth control (either hormonal in the form of contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam/gel or film); or agreement of true abstinence from time to consent is signed until 6 weeks after the last dose of study treatment intervention (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation methods are not considered acceptable methods)
  4. History of immunosuppression
  5. History of hearing or balance problems
  6. Weight < 52kg or > 110kg
  7. Other planned intervention, apart from standard of care
  8. Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ
  9. Lactose intolerance

Sites / Locations

  • Medway Maritime Hospital
  • Kent Oncology Centre, Maidstone Hospital
  • Barking, Havering and Redbridge University Hospitals NHS TrustRecruiting
  • Ashford & St Peters Hospital NHS Foundation TrustRecruiting
  • University Hospitals of Derby and Burton NHS Foundation TrustRecruiting
  • St George's University Hospitals NHS Fundation Trust
  • Norfolk & Norwich University Hospitlas NHS FTRecruiting
  • Shrewsbury and Telford Hospital NHS TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Artesunate

Matching placebo

Arm Description

Artesunate 200mg oral tablets once daily for 14 days.

Matching placebo oral tablets once daily for 14 days.

Outcomes

Primary Outcome Measures

Recurrence free survival at 2 years

Secondary Outcome Measures

Recurrence free survival at 5 years
Overall survival at 2 and 5 years
Colon cancer specific death at 2 and 5 years
Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Pathological assessment of tumour regression (involvement of lymph nodes; serosa; resection margin)
Patient quality of life
Using validated quality of life self-administered questionnaires
Patient quality of life
Using validated quality of life self-administered questionnaires
Patient quality of life
Using validated quality of life self-administered questionnaires
Patient quality of life
Using validated quality of life self-administered questionnaires
Surgical complications
Number of patients with surgery related adverse events as assessed by CTCAE v4.0
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy
Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status
Number of patients with Kras mutant tumours
Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status
Number of patients with Mismatch Repair (MMR) mutant tumours
Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status
Number of patients with BRAF mutant tumours
Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression
Number of patients whose tumours show PDGF upregulation/downregulation following treatment intervention
Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor receptor (PDGFR) expression
Number of patients whose tumours show PDGFR upregulation/downregulation following study intervention
Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression
Number of patients whose tumours show VEGF upregulation/downregulation following study intervention
Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression
Number of patients whose tumours show VEGFR upregulation/downregulation following study intervention
Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining)
Number of patients whose tumours show an increase or reduction in proliferation markers Ki67 and CD31 following study intervention
Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway
Number of patients whose tumour samples show activation of the DDR pathway following study intervention
Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins)
Number of patients who show an increase or a decrease in expression of proteins involved in the Wnt/β-catenin proliferation pathway (e.g. c-myc and cyclinD1 proteins) following study intervention

Full Information

First Posted
November 18, 2015
Last Updated
October 11, 2022
Sponsor
St George's, University of London
search

1. Study Identification

Unique Protocol Identification Number
NCT02633098
Brief Title
A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer
Acronym
NeoART
Official Title
Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Recruiting
Study Start Date
April 26, 2017 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
October 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
St George's, University of London

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the safety and effectiveness of pre-operative artesunate given orally once a day for 14 days prior to surgery in patients with Stage II/III colorectal cancer. Artesunate is an established antimalarial drug with an excellent safety profile, is well tolerated and affordable. A number of laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells. Two hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200mg daily or a matching placebo for 14 days prior to surgery. Patients will be followed up closely for 5 years to see if giving artesunate preoperatively reduces the risk of cancer recurring after surgery.
Detailed Description
Artesunate is an established antimalarial drug belonging to the artemisinin class of drugs, has an excellent safety profile, is well tolerated and affordable. In last two decades, artemisinins have shown potent and broad anticancer properties in a range of cell lines and animal models, supporting the hypothesis that artemisinins have the potential to be an effective anti-cancer therapy. Multiple potential mechanisms of action include anti-proliferative effects through cell-cycle disruption, reactive oxygen species (ROS) -induced DNA damage, induction of apoptosis, anti-angiogenesis, immunomodulation and induced radiosensitivity. Despite a multi-modality treatment approach to colorectal cancer, 5 year overall survival does not currently exceed 60%. Neoadjuvant pre-operative therapy may be more effective at eradicating micrometastases compared to adjuvant therapy delivered following the delay and immunological stress of surgery. However current neoadjuvant chemotherapy regimens are often associated with significant side effects and may result in a delay in surgery whilst patients recover. A well tolerated, affordable, novel anticancer agent that could be given to patients whilst they wait for surgery, without causing a surgical delay due to treatment related toxicity, would have a significant clinical impact on patient care. The NeoART trial is a phase II multicentre randomised, double blind, placebo controlled trial (RCT) for patients undergoing primary surgery for Stage II/III colorectal cancers. Patients are randomised (1:1 ratio) to receive either a two week course of neoadjuvant artesunate 200mg once daily or matching placebo. Both patients and health care professionals are blinded to treatment allocation arm to minimise outcome-reporting bias. The primary endpoint of the trial is recurrence free survival two years after surgery. Secondary endpoints include 2 and 5 year overall survival, treatment related toxicity, tolerability and patient quality of life. A translational sub-study looking at predictive and prognostic biomarkers is also planned.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Bowel Cancer
Keywords
Artesunate, Artemisinins, Antimalarial, Neoadjuvant, Pre-operative

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Artesunate
Arm Type
Experimental
Arm Description
Artesunate 200mg oral tablets once daily for 14 days.
Arm Title
Matching placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo oral tablets once daily for 14 days.
Intervention Type
Drug
Intervention Name(s)
Artesunate 200mg
Intervention Description
Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matched placebo PO OD for 14 days prior to colorectal resection surgery
Primary Outcome Measure Information:
Title
Recurrence free survival at 2 years
Time Frame
2 years following study randomisation.
Secondary Outcome Measure Information:
Title
Recurrence free survival at 5 years
Time Frame
5 years from study randomisation
Title
Overall survival at 2 and 5 years
Time Frame
2 and 5 years from study randomisation
Title
Colon cancer specific death at 2 and 5 years
Time Frame
2 and 5 years from study randomisation
Title
Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment at Day 7 following start of study intervention (artesunate/matching placebo)
Title
Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment at Day 14 following start of study intervention (artesunate/matching placebo)
Title
Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment at Day 42 following start of study intervention (artesunate/matching placebo)
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment at Day 7 following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment at Day 14 following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment at Day 42 following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 6 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 12 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 18 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 24 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 30 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 36 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 42 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 48 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 54 months following study intervention
Title
Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame
Assessment 60 months following study intervention
Title
Pathological assessment of tumour regression (involvement of lymph nodes; serosa; resection margin)
Time Frame
Post surgical pathology review (following Day 14 of study intervention)
Title
Patient quality of life
Description
Using validated quality of life self-administered questionnaires
Time Frame
Assessment at Day 1 of study intervention
Title
Patient quality of life
Description
Using validated quality of life self-administered questionnaires
Time Frame
Assessment at Day 7 of study intervention
Title
Patient quality of life
Description
Using validated quality of life self-administered questionnaires
Time Frame
Assessment at Day 14 of study intervention
Title
Patient quality of life
Description
Using validated quality of life self-administered questionnaires
Time Frame
Assessment at Day 42 of study intervention
Title
Surgical complications
Description
Number of patients with surgery related adverse events as assessed by CTCAE v4.0
Time Frame
From time of surgery up to 3 months post surgery
Title
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy
Time Frame
Assessment at Day 1 of study intervention
Title
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy
Time Frame
Assessment at Day 7 of study intervention
Title
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy
Time Frame
Assessment at Day 14 of study intervention
Title
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy
Time Frame
Assessment at Day 42 of study intervention
Title
Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status
Description
Number of patients with Kras mutant tumours
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status
Description
Number of patients with Mismatch Repair (MMR) mutant tumours
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status
Description
Number of patients with BRAF mutant tumours
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression
Description
Number of patients whose tumours show PDGF upregulation/downregulation following treatment intervention
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor receptor (PDGFR) expression
Description
Number of patients whose tumours show PDGFR upregulation/downregulation following study intervention
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression
Description
Number of patients whose tumours show VEGF upregulation/downregulation following study intervention
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression
Description
Number of patients whose tumours show VEGFR upregulation/downregulation following study intervention
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining)
Description
Number of patients whose tumours show an increase or reduction in proliferation markers Ki67 and CD31 following study intervention
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway
Description
Number of patients whose tumour samples show activation of the DDR pathway following study intervention
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)
Title
Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins)
Description
Number of patients who show an increase or a decrease in expression of proteins involved in the Wnt/β-catenin proliferation pathway (e.g. c-myc and cyclinD1 proteins) following study intervention
Time Frame
Pre and post intervention tumour samples from patients (Day 0 and Day 15)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Aged 18 or over Histologically proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer Stage II/III colorectal cancer planned for surgical resection and no clinical indication for neoadjuvant preoperative chemotherapy/chemoradiation therapy WHO performance status 0,1 or 2 Adequate full blood count: White Cell Count (WCC) >3.0 x 10^9 /l; Platelets >100 x 10^9/l; Haemoglobin (Hb) >80g/L Adequate renal function: Glomerular Filtration Rate >30ml/min by Cockcroft-Gault formula Adequate hepatobiliary function : Bilirubin < 3 x Upper limit normal Female participants of child bearing potential must have a negative pregnancy test < 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention Male participants with a partner of childbearing potential must agree to use adequate, medically approved contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention Patient able and willing to provide written, informed consent for the study. Exclusion criteria Contraindication to the use of artesunate due to hypersensitivity Pregnancy or lactation Male or female participants unwilling to use an effective method of birth control (either hormonal in the form of contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam/gel or film); or agreement of true abstinence from time to consent is signed until 6 weeks after the last dose of study treatment intervention (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation methods are not considered acceptable methods) History of immunosuppression History of hearing or balance problems Weight < 52kg or > 110kg Other planned intervention, apart from standard of care Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ Lactose intolerance
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Professor Sanjeev Krishna, FRCP, ScD, FMedSci
Phone
++44(0)208 725 5836
Email
s.krishna@sgul.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Dr Yolanda Augustin, MBBS, MRCP, FRCR, MSc
Phone
++44(0)2087255722
Email
yaugusti@sgul.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Professor Sanjeev Krishna, BMBCh, DPhil, ScD
Organizational Affiliation
St George's University Hospitals NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medway Maritime Hospital
City
Gillingham
State/Province
Kent
ZIP/Postal Code
ME7 5NY
Country
United Kingdom
Individual Site Status
Completed
Facility Name
Kent Oncology Centre, Maidstone Hospital
City
Maidstone
State/Province
Kent
ZIP/Postal Code
ME16 9QQ
Country
United Kingdom
Individual Site Status
Completed
Facility Name
Barking, Havering and Redbridge University Hospitals NHS Trust
City
Barking
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nirooshun Dr Rajendran
Phone
01708 435000
Ext
3615
Email
nirooshun.rajendran@bhrhospitals.nhs.uk
First Name & Middle Initial & Last Name & Degree
Alison Ray
Phone
01708 435000
Ext
3615
Email
alison.ray@bhrhospitals.nhs.uk
Facility Name
Ashford & St Peters Hospital NHS Foundation Trust
City
Chertsey
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pasha Mr Nisar
Phone
01932 722318
Email
pasha.nisar@asph.nhs.uk
First Name & Middle Initial & Last Name & Degree
Victoria Frost
Phone
01932 723534
Email
victoria.frost@asph.nhs.uk
Facility Name
University Hospitals of Derby and Burton NHS Foundation Trust
City
Derby
ZIP/Postal Code
DE22 3NE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stelios Vakis
Phone
01283 566333
Email
s.vakis@nhs.net
First Name & Middle Initial & Last Name & Degree
Helen Cox
Phone
01283 56633
Email
helena.cox1@nhs.net
Facility Name
St George's University Hospitals NHS Fundation Trust
City
London
ZIP/Postal Code
SW17 0RE
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Norfolk & Norwich University Hospitlas NHS FT
City
Norwich
ZIP/Postal Code
NR4 7UY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adam Stearns
Phone
01603 287372
Email
adam.stearns@nnuh.nhs.uk
First Name & Middle Initial & Last Name & Degree
Cheryl Websdale
Phone
01603 288894
Facility Name
Shrewsbury and Telford Hospital NHS Trust
City
Shrewsbury
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jon Mr Lacy-Colson
Phone
01743 261000
Ext
1460
Email
jon.lacy-colson@sath.nhs.uk
First Name & Middle Initial & Last Name & Degree
Sally Potts
Phone
01743 261000
Ext
1692

12. IPD Sharing Statement

Learn more about this trial

A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer

We'll reach out to this number within 24 hrs